All XRAYs
Relevance: Medium-High
Most relevant for: Women at high risk of ovarian cancer who are considering undergoing risk-reducing surgery.
Study: Women support delayed removal of ovaries
Risk-reducing early removal of fallopian tubes followed by removal of ovaries at a later date was acceptable to women at high risk of ovarian cancer due to an inherited mutation in a recent study. This was especially true for women worried about sexual dysfunction associated with surgical menopause. (12/24/20)
READ MORE ›
Relevance: High
Most relevant for: People with advanced colorectal cancer and a type of biomarker called MSI-High (MSI-H)
Study: Immunotherapy drug Keytruda received FDA approval and showed benefit for treatment of colorectal cancer
In June 2020, the FDA approved Keytruda (pembrolizumab) as an initial therapy for advanced colorectal cancer. This approval was based on the results from the KEYNOTE-177 study. In this study, Keytruda was more successful than chemotherapy in delaying progression of certain types of colorectal cancers. (11/25/20)
READ MORE ›
Relevance: High
Most relevant for: People with metastatic triple-negative breast cancer
Study: Trodelvy clinical trial results likely practice-changing for people with metastatic triple-negative breast cancer
The ASCENT study confirmed an earlier study and showed that the drug sacituzumab govitecan-hizy (Trodelvy) improves outcomes for people with previously treated metastatic triple-negative breast cancer. These results further support the use of Trodelvy as a standard therapy for patients with pretreated metastatic triple-negative breast cancer. (11/20/20)
READ MORE ›
Relevance: Medium-Low
Most relevant for: People with breast cancer particularly those with HER2-positive or triple-negative breast cancer.
Study: The buzz about honeybee venom: Promising early research to treat breast cancer
Early research showed that melittin, an ingredient in honeybee venom, may be used to treat HER2-positive and triple-negative breast cancers. This study found that melittin can kill cancer cells. The chemotherapy drug docetaxel more effectively killed breast cancer cells in mice when combined with melittin. It is not known whether melittin would be safe or affect cancer growth in people. While promising, more research must be done before melittin could be used to treat people. (11/10/20)
READ MORE ›
Relevance: Medium-High
Most relevant for: Young women with, or at high risk for an inherited BRCA mutation
Study: Knowing about an inherited BRCA mutation improves outcomes for women with breast cancer
Inherited mutations in the BRCA1 and BRCA2 genes are linked to a high lifetime risk of breast and other cancers. This study shows that women who know that they have a BRCA mutation before they are diagnosed with breast cancer have improved outcomes including diagnosis at earlier stages and improved overall survival. (10/26/20)
READ MORE ›
Relevance: Medium-High
Most relevant for: Men with high-risk prostate cancer
Study: New imaging technology shows promise in detecting of spread of prostate cancer
A new imaging technique is currently being tested to see if it can detect the spread of prostate cancer sooner than standard imaging. Two clinical trials show that the new technique can detect the spread of prostate cancer in men who are newly diagnosed and in men whose cancer returns after treatment. (10/16/20)
READ MORE ›
Relevance: High
Most relevant for: People who receive chemotherapy for cancer treatment
Personal Story: Coping with chemotherapy-induced hair loss
Ovarian cancer survivor Stephanie Hess shared her personal story about how she coped with hair loss. This XRAY review also includes treatments to reduce this common side effect of chemotherapy. (9/28/20)
READ MORE ›.jpg)
Relevance: Medium-High
Most relevant for: People with metastatic triple-negative breast cancer
Guideline: FDA issues alert on a drug combination to treat triple-negative breast cancer
The immunotherapy drug Tecentriq (atezolizumab) is approved for use with Abraxane (nab-paclitaxel) to treat metastatic triple-negative breast cancer. Tecentriq is NOT approved for use with Taxol (paclitaxel). The Food and Drug Administration has issued an alert to doctors, researchers and patients warning that Tecentriq should not be used in combination with Taxol to treat patients with advanced triple-negative breast cancer. (09/18/20)
READ MORE ›
Relevance: Medium-Low
Most relevant for: Women who consume dairy or soy
Study: Dairy milk may slightly raise breast cancer risk
Debate continues about whether consuming soy or dairy products increases breast cancer risk. This study looked at a large number of women and found no link between soy and breast cancer risk. The study did find that postmenopausal women who drank dairy milk have a small increase in breast cancer risk. (09/04/20)
READ MORE ›
Relevance: High
Most relevant for: Women diagnosed with breast cancer who do not know if they have an inherited mutation in a gene linked to breast cancer
Study: Among women with breast cancer, who should have genetic testing for an inherited mutation?
Which breast cancer patients should consider genetic testing? Knowing whether you have an inherited mutation may inform the decisions you and your healthcare provider make about treatment. But it can also increase stress and anxiety. This XRAY reviews a study of how different guidelines affect genetic testing recommendations for people with breast cancer. (8/27/20)
READ MORE ›